Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiangshuo Li

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Molecules (Basel, Switzerland)|February 25, 2022
Molecular Pathological Diagnosis of Thyroid Tumors Using Spatially Resolved MetabolomicsLuojiao Huang, Xinxin Mao, Chenglong Sun, et al.
Clinical Pharmacology in Drug Development|July 3, 2025
A Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-101, an RNAi Therapeutic Targeting HBV InfectionJianxiong Zhang, Jiangshuo Li, Le Wu, et al.
Clinical and Translational Science|November 13, 2024
Evaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjectsJingcheng Chen, Jingxuan Wu, Nini Guo, et al.
Clinical and Translational Science|June 25, 2026
Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy ParticipantsJingcheng Chen, Jingxuan Wu, Yuqin Song, et al.
British Journal of Pharmacology|February 23, 2026
Development of a novel tyrosine kinase 2 inhibitor ARTS-011 and its first-in-human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effectsZhili Jin, Jingxuan Wu, Jiaqi Liang, et al.
The Journal of Infection|October 28, 2023
Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adultsZhili Jin, Jingxuan Wu, Ying Wang, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Molecules (Basel, Switzerland)|February 25, 2022
Molecular Pathological Diagnosis of Thyroid Tumors Using Spatially Resolved MetabolomicsLuojiao Huang, Xinxin Mao, Chenglong Sun, et al.
Clinical Pharmacology in Drug Development|July 3, 2025
A Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-101, an RNAi Therapeutic Targeting HBV InfectionJianxiong Zhang, Jiangshuo Li, Le Wu, et al.
Clinical and Translational Science|November 13, 2024
Evaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjectsJingcheng Chen, Jingxuan Wu, Nini Guo, et al.
Clinical and Translational Science|June 25, 2026
Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy ParticipantsJingcheng Chen, Jingxuan Wu, Yuqin Song, et al.
British Journal of Pharmacology|February 23, 2026
Development of a novel tyrosine kinase 2 inhibitor ARTS-011 and its first-in-human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effectsZhili Jin, Jingxuan Wu, Jiaqi Liang, et al.
The Journal of Infection|October 28, 2023
Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adultsZhili Jin, Jingxuan Wu, Ying Wang, et al.
Pageof 2